Skip to main content
SpringerLink
Log in

Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease

  • Interventional Cardiology (S Rao, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Endovascular management of superficial femoral artery disease has historically been limited to percutaneous balloon angioplasty, atherectomy, and bare-metal stents. However, these therapies have been plagued by high restenosis and target lesion revascularization rates. More recent technologies such as drug-coated stents and balloons are designed to combat restenosis by locally delivering antiproliferative drugs. Several randomized controlled trials have directly compared these antiproliferative drug-delivering devices to their non-drug-coated counterparts. Additionally, trials are currently ongoing to compare use of drug-coated technologies in combination with traditional therapies in hope of synergistic effects. This review gathers data from currently published clinical trials, provides an overview of upcoming clinical studies utilizing drug-coated technology, and explores the possible impact these devices may have on clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–43.

    Article  PubMed  Google Scholar 

  2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.

    Article  CAS  PubMed  Google Scholar 

  3. Wood NB, Zhao SZ, Zambanini A, et al. Curvature and tortuosity of the superficial femoral artery: a possible risk factor for peripheral arterial disease. J Appl Physiol. 2006;101:1412–8.

    Article  CAS  PubMed  Google Scholar 

  4. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–92.

    Article  CAS  PubMed  Google Scholar 

  5. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991;83:I70–80.

    Article  CAS  PubMed  Google Scholar 

  6. Nadal LL, Cynamon J, Lipsitz EC, Bolia A. Subintimal angioplasty for chronic arterial occlusions. Tech Vasc Interv Radiol. 2004;7:16–22.

    Article  PubMed  Google Scholar 

  7. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229–34.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. New Engl J Med. 2006;354:1879–88.

    Article  CAS  PubMed  Google Scholar 

  9. Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Cath Cardiovasc Interv. 2009;74:1090–5.

    Article  Google Scholar 

  10. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–76.

    Article  PubMed  Google Scholar 

  11. Chalmers N, Walker PT, Belli AM, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol. 2013;36:353–61.

    Article  PubMed  Google Scholar 

  12. Lepantalo M, Laurila K, Roth WD, et al. PTFE bypass or thrupass for superficial femoral artery occlusion? A randomised controlled trial. Eur J Vasc Endovasc. 2009;37:578–84.

    Article  CAS  Google Scholar 

  13. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48:1573–8.

    Article  PubMed  Google Scholar 

  14. Banerjee S, Pershwitz G, Sarode K, et al. Stent and non-stent based outcomes of infrainguinal peripheral artery interventions from the multicenter XLPAD registry. J Inv Cardiol 2014.

  15. Sarode K, Spelber DA, Bhatt DL, et al. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. JACC Cardiovasc Interv. 2014;7:827–39. This review provides a thorough description of studies utilizing drug delivering technologies in femoropopliteal and below-the-knee arteries.

    Article  PubMed  Google Scholar 

  16. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852–5.

    Article  CAS  PubMed  Google Scholar 

  17. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–93.

    Article  CAS  PubMed  Google Scholar 

  18. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636–45.

    Article  CAS  PubMed  Google Scholar 

  19. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circulation Res. 2000;86:879–84.

    Article  CAS  PubMed  Google Scholar 

  20. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–10.

    Article  PubMed  Google Scholar 

  21. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.

    Article  PubMed  Google Scholar 

  22. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–27. This study provides data from a multicenter randomized controlled trial comparing drug coated stents to percutaneous transluminal angioplasty and provisional bare metal stenting. Also included are results from a large sample single-arm trial which incorporates increased disease and lesion severity.

    Article  CAS  PubMed  Google Scholar 

  23. The proven effect of Zilver PTX at 4 years. Available at https://www.cookmedical.com/data/resources/clinicalReferences/PI-NAM-11371-EN-201312-M3.pdf. Accessed November 26, 2014.

  24. Yokoi H. Zilver PTX Japan PMS. Presented at Vascular Interventional Advances Scientific Sessions. Las Vegas. 2014.

  25. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65.

    Article  CAS  PubMed  Google Scholar 

  26. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med. 2008;358:689–99.

    Article  CAS  PubMed  Google Scholar 

  27. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–40.

    Article  CAS  PubMed  Google Scholar 

  28. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–9.

    Article  PubMed  Google Scholar 

  29. Schienert D. Biolux P-I: First in-human randomized controlled trial of Passeo-18 Lux DRB vs. POBA in femoropopliteal arteries: 12 month results. Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Sessions. San Francisco. 2013.

  30. Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21:1–8.

    Article  PubMed  Google Scholar 

  31. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295–302.

    Article  PubMed  Google Scholar 

  32. Karimi A, de Boer SW, van den Heuvel DA, et al. Randomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial. Trials. 2013;14:87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Tacke J. TCT-268 Randomized clinical trial favors the use of drug-coated balloons over plain balloons for the postdilatation of nitinol stents in the SFA and PI segment to lower restenosis rate. Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Sessions. Washington, DC. 2014.

  34. Zeller T. DEFINITIVE-AR 12-month results: directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency. Presented at Vascular Interventional Advances (VIVA) Scientific Sessions. Las Vegas. 2014.

  35. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58:682–6.

    Article  PubMed  Google Scholar 

  36. Kearns BC, Michaels JA, Stevenson MD, Thomas SM. Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. Br J Surg. 2013;100:1180–8.

    Article  CAS  PubMed  Google Scholar 

  37. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003;24:1462–7.

    Article  CAS  PubMed  Google Scholar 

  38. Sarode K. TCT-523 Multicenter Registry for Peripheral Arterial Disease Interventions and Outcomes (XLPAD Registry). Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Sessions. San Francisco. 2013.

  39. Safian R, Freed, MS. Manual of interventional cardiology, Abridged. 3rd Edition ed: Jones & Bartlett Learning. 2001.

  40. Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endvoasc Ther. 2012;19:571–80.

    Article  Google Scholar 

  41. Rosenfield K. 12-month LEVANT 2 results. Presented at Vascular Interventional Advances (VIVA) Scientific Sessions. Las Vegas. 2014.

  42. Evaluation of paclitaxel eluting stent vs. paclitaxel eluting balloon treating peripheral artery disease of the femoral artery. Available at http://clinicaltrials.gov/ct2/show/NCT01728441.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Subhash Banerjee reports research grants from Boston Scientific and Medicines Company; consultant/speaker honoraria from Gilead, St. Jude Medical, Cordis, Boehringer Ingelheim, Sanofi, and Medtronic; ownership with MDCARE Global (spouse); intellectual property with HygeiaTel.

Karan Sarode and Atif Mohammad declare that they have no conflict of interest.

Emmanouil S. Brilakis reports consulting honoraria/speaker fees from Sanofi, Janssen, St. Jude Medical, Terumo, Somahlution, Elsevier, Asahi, Abbott Vascular, and Boston Scientific; research grant from Guerbet; spouse is an employee of Medtronic.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Veteran Affairs North Texas Healthcare System, 4500 S Lancaster Road (111A), Dallas, TX, 75216, USA

    Subhash Banerjee, Karan Sarode, Atif Mohammad & Emmanouil S. Brilakis

  2. University of Texas Southwestern Medical Center, Dallas, TX, USA

    Subhash Banerjee, Atif Mohammad & Emmanouil S. Brilakis

Authors
  1. Subhash Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karan Sarode
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atif Mohammad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanouil S. Brilakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Subhash Banerjee.

Additional information

This article is part of the Topical Collection on Interventional Cardiology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Banerjee, S., Sarode, K., Mohammad, A. et al. Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease. Curr Cardiol Rep 17, 36 (2015). https://doi.org/10.1007/s11886-015-0586-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-015-0586-8

Keywords

Search

Navigation